{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:28:52Z","timestamp":1748971732417},"reference-count":39,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T00:00:00Z","timestamp":1396828800000},"content-version":"vor","delay-in-days":341,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Top Institute Pharma (Leiden, The Netherlands","award":["D2-104"],"award-info":[{"award-number":["D2-104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.schres.2013.02.011","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:31:57Z","timestamp":1362616317000},"page":"144-152","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacokinetic\u2013pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility"],"prefix":"10.1016","volume":"146","author":[{"given":"Venkatesh","family":"Pilla Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kozielska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Abbas","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik","family":"de Greef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geny M.M.","family":"Groothuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes H.","family":"Proost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.02.011_bb0005","series-title":"NONMEM User's Guides. (1989\u20132009)","author":"Beal","year":"2009"},{"key":"10.1016\/j.schres.2013.02.011_bb0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1208\/s12248-009-9123-2","article-title":"Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease","volume":"11","author":"Bhattaram","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.schres.2013.02.011_bb0015","first-page":"S19","article-title":"Population pharmacokinetics (PPK) of paliperidone er in healthy and schizophrenia patients","volume":"81","author":"Cirincione","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.02.011_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1208\/s12248-010-9247-4","article-title":"Dopamine D(2) occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms","volume":"13","author":"de Greef","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.schres.2013.02.011_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01621459.1987.10478410","article-title":"Better bootstrap confidence-intervals","volume":"82","author":"Efron","year":"1987","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.schres.2013.02.011_bb0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2013.02.011_bb0040","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1177\/0091270010378409","article-title":"Missing data in model-based pharmacometric applications: points to consider","volume":"50","author":"Gastonguay","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2013.02.011_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jpsychires.2009.11.004","article-title":"Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment","volume":"44","author":"Giegling","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2013.02.011_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/clpt.2011.197","article-title":"A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information","volume":"91","author":"Goyal","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1023249510224","article-title":"A joint model for nonlinear longitudinal data with informative dropout","volume":"30","author":"Hu","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.schres.2013.02.011_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.schres.2013.02.011_bb0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","article-title":"What is causing the reduced drug\u2013placebo difference in recent schizophrenia clinical trials and what can be done about it?","volume":"36","author":"Kemp","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.011_bb0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mcp.2000.110975","article-title":"Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model","volume":"68","author":"Kimko","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pst.267","article-title":"Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches","volume":"7","author":"Lane","year":"2008","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.schres.2013.02.011_bb0080","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/clpt.2010.229","article-title":"What is clinical utility and why should we care?","volume":"88","author":"Lesko","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2013.02.011_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit \u2014 a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.schres.2013.02.011_bb0095","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/clpt.2011.242","article-title":"Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics \u2014 a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2013.02.011_bb0105","series-title":"Pharmacometrics: The Science of Quantitative Pharmacology","first-page":"547","article-title":"Developing models of disease progression","author":"Mould","year":"2007"},{"key":"10.1016\/j.schres.2013.02.011_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-based meta-analysis: an important tool for making quantitative decisions during drug development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.011_bb0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-010-0812-7","article-title":"Serum concentrations of paliperidone versus risperidone and clinical effects","volume":"66","author":"Nazirizadeh","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2013.02.011_bb0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/17460440903036073","article-title":"Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity","volume":"4","author":"Nucci","year":"2009","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.schres.2013.02.011_bb0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.011_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-11-113","article-title":"Is the PANSS used correctly? a systematic review","volume":"11","author":"Obermeier","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2013.02.011_bb0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11590590-000000000-00000","article-title":"Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders","volume":"50","author":"Pilla Reddy","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2013.02.011_bb0140","series-title":"20th Population Approach Group in Europe; 2011 Jun 07\u201310; Athens, Greece [online]","article-title":"Exposure\u2013response relationship of typical and atypical antipsychotics assessed by the Positive and Negative Syndrome Scale (PANSS) and its subscales","author":"Pilla Reddy","year":"2011"},{"key":"10.1016\/j.schres.2013.02.011_bb0145","doi-asserted-by":"crossref","unstructured":"Pilla Reddy, V., Kozielska, M., Johnson, M., Mafirakureva, N., Vermeulen, A., Liu, J., de Greef, R., Groothuis, G.M.M., Rujescu, D., Danhof, M., Proost, J.H., 2012a. Population pharmacokinetic and pharmacodynamic modeling of haloperidol in patients with schizophrenia using Positive and Negative Syndrome Rating Scale. Unpublished results.","DOI":"10.1097\/JCP.0b013e3182a4ee2c"},{"key":"10.1016\/j.schres.2013.02.011_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11598460-000000000-00000","article-title":"Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials","volume":"51","author":"Pilla Reddy","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2013.02.011_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/pst.355","article-title":"Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis","volume":"8","author":"Ploeger","year":"2009","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.schres.2013.02.011_bb0165","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/schbul\/sbm161","article-title":"The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data","volume":"34","author":"Rabinowitz","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.011_bb0170","series-title":"Statistical Analysis with Missing Data","author":"Roderick","year":"2002"},{"key":"10.1016\/j.schres.2013.02.011_bb0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2013.02.011_bb0180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.schres.2013.02.011_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.schres.2013.02.011_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10928-006-9040-2","article-title":"Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder","volume":"34","author":"Vermeulen","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.schres.2013.02.011_bb0195","doi-asserted-by":"crossref","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic\u2013pharmacodynamic analysis","volume":"4","author":"Wahlby","year":"2002","journal-title":"AAPS J."},{"key":"10.1016\/j.schres.2013.02.011_bb0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-200241020-00006","article-title":"Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients","volume":"41","author":"Yukawa","year":"2002","journal-title":"Clin. Pharmacokinet."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T11:31:10Z","timestamp":1562758270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":39,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0920996413001035"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.02.011","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}